Drugs / RO6839921
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02098967 | Apr 2014 → May 2018 | acute myeloid leukemia | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO6839921 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02098967 ↗ |
| Action | Inhibit | “RO6839921 is an inactive pegylated prodrug of the oral MDM2 antagonist idasanutlin” PMID 32020437 ↗ Feb 2020 |
| Route | Intravenous | “In both arms, RO6839921 will be administered by IV infusion on Days 1-5 of 28-day cycles.” NCT02098967 ↗ |
| Target | MDM2 | “RO6839921 is an inactive pegylated prodrug of the oral MDM2 antagonist idasanutlin” PMID 32020437 ↗ Feb 2020 |